Heron Therapeutics Inc vs Tesla, Inc. — how do they compare? Heron Therapeutics Inc trades at $0.46 (market cap $91.46M), while Tesla, Inc. trades at $379.25 (market cap $1.39T). The key difference: Tesla, Inc. is far larger — about 15197.9× Heron Therapeutics Inc's market cap, and Tesla, Inc. is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | TSLA | |
|---|---|---|
Market Cap | $91.46M | $1.39T |
Sector | Health | Consumer Cyclical |
52-Week High | $1.96 | $489.88 |
52-Week Low | $0.39 | $302.63 |
Enterprise Value | $189.36M | $1.36T |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Tesla (TSLA) trades at $378.88, down 0.51% with a bearish technical outlook. The stock faces valuation concerns with a P/E of 339 and declining profitability margins, though recent earnings beat expectations. Cash flow remains positive despite heavy capital investments. European regulatory approval for driver-assistance software and German sales growth provide optimism, but competition and slowing auto business present challenges.
Tesla's outlook balances innovation potential against execution risks. The stock offers growth exposure to AI and autonomy but carries premium valuation and competitive pressures. Near-term catalysts include Q2 earnings and robotaxi developments, while margin compression and market sentiment shifts represent key investor risks.
Trailing returns across standard periods
Latest headlines on both assets
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →